BeOne Medicines Ltd. (ONC) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	6.1B	5.3B	3.8B	2.5B	1.4B
Cost of Revenue	680.7M	668.5M	594.1M	379.9M	286.5M
Gross Profit	5.4B	4.7B	3.2B	2.1B	1.1B
Operating Expenses
R&D Expense	2.3B	2.1B	2.0B	1.8B	1.6B
SG&A Expense	2.2B	2.1B	1.8B	1.5B	1.3B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	4.5B	4.2B	3.8B	3.3B	2.9B
Cost and Expenses	5.2B	4.9B	4.4B	3.7B	3.2B
Operating Income (EBIT)	923.1M	447.1M	(568.2M)	(1.2B)	(1.8B)
Non-Operating
Interest Income	116.7M	70.5M	47.8M	74.0M	52.5M
Interest Expense	72.6M	58.2M	—	—	—
Net Interest Income	44.1M	12.3M	47.8M	74.0M	52.5M
Other Non-Op Income/Expense	(55.0M)	(30.3M)	35.2M	381.9M	(171.4M)
Non-Operating Income (excl Interest)	(81.4M)	(28.0M)	(35.2M)	(381.9M)	171.4M
EBT (Pre-Tax Income)	868.1M	416.9M	(533.0M)	(825.8M)	(2.0B)
Income Tax Expense	212.4M	129.9M	111.8M	55.9M	42.8M
Bottom Line
Net Income	655.7M	286.9M	(644.8M)	(881.7M)	(2.0B)
Earnings from Cont. Ops	655.7M	286.9M	(644.8M)	(881.7M)	(2.0B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	655.7M	286.9M	(644.8M)	(881.7M)	(2.0B)
Per Share
Basic EPS	$76.05	$33.80	($6.12)	($8.45)	($19.37)
Diluted EPS	$72.28	$32.11	($6.12)	($8.45)	($19.37)
Revenue Per Share	$54.93	$48.99	$36.19	$23.55	$13.73
Shares
Basic Shares Outstanding	111.6M	109.1M	105.3M	104.4M	103.1M
Diluted Shares Outstanding	115.8M	113.4M	105.3M	104.4M	103.1M
Profitability Metrics
EBITDA	1.2B	616.8M	(361.2M)	(738.2M)	(1.9B)
D&A	154.9M	141.7M	171.8M	87.7M	66.3M
EBIT	1.0B	475.1M	(533.0M)	(825.8M)	(2.0B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026